(Nevada, Las Vegas) United States, DelveInsight’s, “Alpha Thalassemia – Pipeline Insight, 2023,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in the Alpha Thalassemia pipeline landscape.
Key Takeaways from the Alpha Thalassemia Pipeline Report
- Over 4+ companies and 4+ pipeline drugs in Alpha1-Antitrypsin Deficiency (AATD) pipeline landscape and their anticipated acceptance in the Alpha Thalassemia market would significantly increase market revenue.
- Leading Alpha Thalassemia companies developing novel drug candidates to improve the Alpha Thalassemia treatment landscape include Agios Inc and others.
- Promising Alpha Thalassemia pipeline therapies in various stages of development include Mitapivat and others
Alpha Thalassemia Overview
Alpha thalassemia is an inherited blood disorder that results in the reduced production of hemoglobin. Haemoglobin is an essential protein that is involved in the transportation of oxygen throughout the body. Alpha thalassemia is caused due to mutations in genes responsible for the production of alpha-globin. Depending on the number of alpha globin genes affected, it can result in four types of alpha thalassemia-silent alpha thalassemia, alpha thalassemia minor, hemoglobin H disease, and alpha thalassemia major or hydrops details.
Alpha Thalassemia Pipeline Analysis: Drug Profile
Mitapivat: Agios,Inc.
Agios Inc’s investigational drug candidate Mitaoivat is an activator of mutated as well as normal pyruvate kinase-R (PKR) enzymes. The drug is primarily being studied for PK deficiency but the company has expanded its research and clinical application of mitapavit into thalassemia as well as sickle cell disease. The drug is currently in the Phase II trial for thalassemia. The U.S. Food and Drug Administration granted the Orphan Drug Status to Mitapivat for the treatment of thalassemia.
Discover more about the emerging Alpha Thalassemia drugs @ Alpha Thalassemia Treatment Drugs
Alpha Thalassemia Pipeline Therapies and Key Companies
- Mitapivat: Agios
And others
Alpha Thalassemia Pipeline Therapeutics Assessment
DelveInsight’s Report covers around 4+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Alpha1-Antitrypsin Deficiency (AATD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- Subcutaneous
- Intramuscular
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like mono, Combination, and Mono/Combination.
Scope of the Alpha Thalassemia Pipeline Report
- Coverage: Global
- Key Alpha1 Antitrypsin Deficiency Companies: Agios, Inc and many others.
- Key Alpha Thalassemia Pipeline Therapies: Mitapivat and many others
Find out more about the Alpha Thalassemia treatment options in development @ Alpha Thalassemia Clinical Trials
Table of Contents
1. Alpha Thalassemia Introduction
2. Alpha Thalassemia Executive Summary
3. Alpha Thalassemia Overview
4. Alpha Thalassemia Pipeline Therapeutics
5. Alpha Thalassemia Late-Stage Products (Phase III)
6. Alpha Thalassemia Mid-Stage Products (Phase II)
7. Alpha Thalassemia Early Stage Products (Phase I/II)
8. Alpha Thalassemia Preclinical Stage Products
9. Alpha Thalassemia Discovery Stage Products
10. Alpha Thalassemia Therapeutic Assessment
11. Alpha Thalassemia Inactive Products
12. Alpha Thalassemia Collaborations Assessment- Licensing / Partnering / Funding
13. Alpha Thalassemia Unmet Needs
14. Alpha Thalassemia Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
